MedImmune

From Food & Medicine Encyclopedia

MedImmune, LLC is an American biotechnology company, which was acquired by AstraZeneca in 2007. The company's primary products are Synagis, FluMist, and Imfinzi, which are used for the prevention of Respiratory Syncytial Virus (RSV) and treatment of influenza and bladder cancer respectively.

History[edit]

MedImmune was founded in 1988 by Wayne Hockmeyer. It was initially a privately held company, but became publicly traded in 1991. In 2007, it was acquired by AstraZeneca for $15.6 billion.

Products[edit]

MedImmune has three primary products: Synagis, FluMist, and Imfinzi.

Synagis[edit]

Synagis is a monoclonal antibody used for the prevention of serious lower respiratory tract disease caused by RSV in pediatric patients.

FluMist[edit]

FluMist is a nasal spray influenza vaccine that protects against four strains of influenza.

Imfinzi[edit]

Imfinzi is a human monoclonal antibody that is designed to bind with PD-L1 and block the interaction of PD-L1 with PD-1 and CD80.

Research and Development[edit]

MedImmune conducts research in several areas of study, including oncology, respiratory, cardiovascular and metabolic disease, and infection and vaccines.

See Also[edit]

Stub icon

This medical article is a stub. You can help WikiMD by expanding the page.

  • MedImmune
    MedImmune

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=MedImmune&oldid=6335416"